360 related articles for article (PubMed ID: 23151021)
1. Molecular characterisation of cell line models for triple-negative breast cancers.
Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
[TBL] [Abstract][Full Text] [Related]
2. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.
Dutta B; Pusztai L; Qi Y; André F; Lazar V; Bianchini G; Ueno N; Agarwal R; Wang B; Shiang CY; Hortobagyi GN; Mills GB; Symmans WF; Balázsi G
Br J Cancer; 2012 Mar; 106(6):1107-16. PubMed ID: 22343619
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
5. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
6. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
7. IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.
Christgen M; Geffers R; Kreipe H; Lehmann U
Cancer Sci; 2013 Dec; 104(12):1726-30. PubMed ID: 24344720
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
9. Triple negative tumours: a critical review.
Reis-Filho JS; Tutt AN
Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models.
Voutsadakis IA
Cancer Genomics Proteomics; 2023; 20(6):539-555. PubMed ID: 37889067
[TBL] [Abstract][Full Text] [Related]
11. Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.
Giuliani S; Leonardi E; Aldovini D; Bernardi D; Pellegrini M; Soli F; Ferro A; Dalla Palma P; Decarli N; Barbareschi M
Pathologica; 2012 Jun; 104(3):93-7. PubMed ID: 22931039
[TBL] [Abstract][Full Text] [Related]
12. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer.
Das K; Leong DT; Gupta A; Shen L; Putti T; Stein GS; van Wijnen AJ; Salto-Tellez M
Eur J Cancer; 2009 Sep; 45(13):2239-48. PubMed ID: 19632824
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.
Yamamoto M; Ito T; Shimizu T; Ishida T; Semba K; Watanabe S; Yamaguchi N; Inoue J
Cancer Sci; 2010 Nov; 101(11):2391-7. PubMed ID: 20735436
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 expression in triple negative sporadic breast cancers.
Galizia E; Giorgetti G; Piccinini G; Santinelli A; Loretelli C; Bianchi F; Gagliardini D; Carbonari G; Pisa E; Belvederesi L; Bracci R; Ferretti C; Corradini F; Cellerino R
Anal Quant Cytol Histol; 2010 Feb; 32(1):24-9. PubMed ID: 20701084
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression.
Alshenawy HA
J Egypt Natl Canc Inst; 2012 Jun; 24(2):77-83. PubMed ID: 23582599
[TBL] [Abstract][Full Text] [Related]
18. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
20. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
